Tiziana life sciences starts enrollment of the first patient cohort in its intermediate size patient population expanded access program to evaluate foralumab in non-active secondary multiple sclerosis patients

New york, oct. 26, 2022 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the start of enrollment of the first patient cohort (n=4) in its intermediate size patient population expanded access program to evaluate foralumab in non-active secondary progressive multiple sclerosis (spms) patients. this treatment program will evaluate dosing at the “standard” dosing of 50 mcg and, if needed, a higher 100 mcg dose of intranasal foralumab in two separate cohorts of four non-active spms patients each. the program is being conducted at brigham and women's hospital in boston, massachusetts.
TLSA Ratings Summary
TLSA Quant Ranking